您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

Non-clinical Research-used
Medicine Sample Provider
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 作用于消化系统药物->助消化药物
处方药:处方药
包装规格: 100毫克/片 100片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
安斯泰来
生产厂家英文名:
Astellas & Zeria
该药品相关信息网址1:
http://www.astellas.com/en/corporate/news/detail/launch-of-acofide-in-japan-for.html
原产地英文商品名:
ACOFIDE 100mg 100tabs
原产地英文药品名:
acotiamide
中文参考商品译名:
盐酸阿考替胺片 100毫克/片 100片/盒
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Indigestion
临床试验期:
完成
中文适应病症参考翻译1:
消化不良
药品信息:
英文药名:Acofide(Acotiamide Hydrochloride Hydrate Tablets) 中文药名:盐酸阿考替胺片 生产厂家:安斯泰来 本品由安斯泰来与泽里新药株式会社联合开发,2013.2日本批准上市 商標名 Acofide Tablets 通用名称 Akochiamido盐酸盐水合物(JAN) Acotiamide盐酸盐水合物(JAN) Acotiamide(INN) 化学名称 N-{2 - [双(1 - 甲基乙基)氨基]乙基} -2 - [(2 - 羟基-4,5 - 二甲氧基苯甲酰基)氨基]噻唑-4 - 甲酰胺盐酸盐三水合物 分子式 C21H30N4O5S·HCL·3H2O 分子量 541.06 性状 它是一种浅白色至黄色结晶粉末或晶体。的可溶性的N,N-二甲基甲酰胺,微溶于乙醇(99.5),甲醇,水,2 -微溶于乙腈,丙醇,和极微溶于丙酮。几乎不溶于己烷和乙酸乙酯。 熔点 没有观察到熔点。 效果或疗效 餐后的饱胀感,功能性消化不良,上腹部饱胀,早饱 相关使用说明的效果或疗效 对烧灼感和疼痛在上腹 1、功能性消化不良的有效性得到证实。 2、上消化道内镜检查等,并且要排除器质性的疾病,包括恶性肿瘤,如胃癌。 用法与用量 通常,一天三次,口服一次100毫克饭前Akochiamido盐酸盐水合物在成人。 药理 1、胃肠道蠕动增强效果 显示胃窦运动大鼠和狗餐后胃窦运动程增强提高效果。它还表明可乐定引起胃窦蠕动减少大鼠和狗的改善效果。 2、延迟胃排空改善行动 我发现可乐定引起的大鼠胃排空的改善效果。 3、作用机制。 发现乙酰胆碱酯酶的抑制效果。 Tokyo, June 5, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that Acofide® Tablets 100mg (nonproprietary name: acotiamide hydrochloride hydrate; “Acofide”; Zeria’s development code: “Z-338”; Astellas’s development code: “YM443”) for the treatment of functional dyspepsia (FD) will be launched on June 6, 2013. Acofide, the world first FD treatment which demonstrated efficacy in the patients with FD diagnosed by the Rome III, the international diagnostic criteria for functional gastrointestinal diseases, will be launched in Japan ahead of the rest of the world. Acotiamide hydrochloride hydrate is a new chemical entity originated by Zeria, and inhibits peripheral acetylcholinesterase activities. Acetylcholine is an important neurotransmitter to regulate gastrointestinal motility, and through the inhibition of degradation of acetylcholine, Acofide improves the impaired gastric motility and delayed gastric emptying, and consequently the subjective symptoms of FD such as postprandial fullness, upper abdominal bloating, and early satiation. Also, since Acofide will be the first treatment with FD indication, Zeria and Astellas will co-promote Acofide for the sake of the increase of disease awareness of FD, the prompt market penetration, and the maximization of product potential. We believe that Acofide will contribute to alleviate the subjective symptoms and improve QOL of patients with FD. Upon the launch of Acofide, Zeria and Astellas do not revise their current fiscal year (from April 1, 2013 to March 31, 2014) financial forecasts, respectively.
更新日期: 2021-3-19
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15900659515@163.com